🎉 M&A multiples are live!
Check it out!
Company | Headquarters | Sector | Stock Price | Enterprise Value | EV/Revenue | EV/EBITDA |
---|---|---|---|---|---|---|
AstraZeneca | United Kingdom of Great Britain and Northern Ireland | Biopharmaceuticals, Drug Development & Therapeutics | £107 | $252B | 4.3x | 12.4x |
GSK | United Kingdom of Great Britain and Northern Ireland | Biopharmaceuticals, Drug Development & Therapeutics, Vaccines & Immunotherapies | £14 | $97.6B | 2.3x | 6.6x |
Haleon | United Kingdom of Great Britain and Northern Ireland | Health & Beauty, Drug Development & Therapeutics | £4 | $55.4B | 3.6x | 14.5x |
Hikma Pharmaceuticals | United Kingdom of Great Britain and Northern Ireland | Biopharmaceuticals, Drug Development & Therapeutics | £20 | $7.1B | 2.1x | 8.0x |
HUTCHMED | United Kingdom of Great Britain and Northern Ireland | Biopharmaceuticals, Drug Development & Therapeutics | £2 | $2.1B | 3.1x | -92.0x |
Indivior | United Kingdom of Great Britain and Northern Ireland | Biopharmaceuticals, Drug Development & Therapeutics | £12 | $2.0B | 1.7x | 6.9x |
Oxford BioMedica | United Kingdom of Great Britain and Northern Ireland | Contract Research & Manufacturing, Drug Development & Therapeutics | £4 | $591M | 3.0x | -80.4x |
Allergy Therapuetics | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics, Vaccines & Immunotherapies | £0 | $552M | 6.9x | -21.9x |
Faron Pharmaceuticals | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics, Vaccines & Immunotherapies | £2 | $334M | 390356.6x | -13.8x |
Animalcare Group | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics | £3 | $289M | 2.5x | 13.9x |
4basebio | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics, Genomics & Personalized Medicine | £10 | $185M | 71.4x | -10.0x |
Avacta Group | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics, Pharma Diagnostics & Analytics | £0 | $183M | 2574.5x | -5.3x |
Scancell | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics, Vaccines & Immunotherapies | £0 | $154M | 24.3x | -9.3x |
PureTech Health | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics, Biopharmaceuticals | £1 | $87.2M | 2.7x | -0.6x |
Shield Therapeutics | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics | £0 | $70.6M | 1.6x | -4.5x |
Eco Animal Health Group | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics | £1 | $34.9M | 0.3x | 3.4x |
Futura Medical | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics | £0 | $33.5M | 2.7x | -20.4x |
Celadon Pharma | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics, Cannabis | £0 | $19.1M | N/A | N/A |
Valuation multiples as of last 12 months (LTM). Stock prices as of July 16, 2025. Financial data powered by Morningstar and FactSet.
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.